Illumina Unveils MiSeq i100 Series Sequencing Systems To Advance Next Generation Sequencing For Labs; US List Price Is $49,000 & $109,000 For MiSeq i100 Plus; Available For Global Shipping In 2025

-4.66% Pre

Illumina, Inc.

ILMN

0.00

Designed to make next-generation sequencing accessible to more labs

With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries

SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing systems, delivering unparalleled benchtop speed and simplicity to advance next-generation sequencing (NGS) for labs.

The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, will empower customers to unlock powerful insights through an affordable, comprehensive solution that is simple to understand and use, even for those with limited NGS expertise. Room-temperature storage and shipping enable labs to sequence on demand, with no delays for thaw time, and same-day sample-to-analysis.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.